Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients

Type 2 Diabetes Clinical Trial

Official title:

Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin Compared to Sequential Metformin Therapy in Newly Diagnosed Type 2 Diabetes Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06417489
• Other study ID #: 2024-165-002
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: May 31, 2024
• Est. completion date: December 31, 2026

Study information

• Verified date: May 2024
• Source: Peking University First Hospital
• Contact: Junqing Zhang
• Phone: 8613611167278
• Email: nan.gu[@]pkufh.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluated the efficacy and safety of initial combined treatment of Henggliptin, Retagliptin and Metformin by including new type 2 diabetes patients. This study is a multicenter, randomized, open label, positive control study. It is planned to include 160 new type 2 diabetes patients who meet the inclusion criteria of the study. The study is divided into three stages: screening period (V0, -14d-0), treatment period (V1-V8, D1-24w) and safe follow-up period (V9, 28w), with a total of 10 planned visits. This study was divided into an experimental group and a control group. The experimental group received a one-time addition of 10 mg qd of Henggliptin, 100 mg qd of Regagliptin, and 500mg of Metformin. The control group was first treated with metformin. If the blood sugar level did not meet the standard (fasting blood glucose (FPG)>7mmol/L, postprandial blood glucose (PPG)>10mmol/L), Henggeliflozin 10 mg qd was sequentially added. If the blood sugar level did not meet the standard after 4 weeks, Regagliptin 100 mg qd was added. During the follow-up period, evaluate blood glucose control, pancreatic islet function, and safety in both groups of patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 160
• Est. completion date: December 31, 2026
• Est. primary completion date: May 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Untreated newly diagnosed T2DM patients;

2. Age = 18 years old;

3. 8.0% = HbA1c<11.0%;

4. 19 kg/m2 = BMI<35 kg/m2;

5. eGFR = 60 ml/min1.73m2;

6. Voluntarily participate and sign an informed consent form

Exclusion Criteria:

1. Pregnant and lactating women, as well as women of childbearing age who are unwilling to take reliable contraceptive measures;

2. Individuals who are known to be allergic to Henggliflozin, Regagliptin, or Metformin;

3. Other types of diabetes except type 2 diabetes;

4. Type 2 diabetes with a history of ketoacidosis (DKA) in the last 6 months;

5. NYHA cardiac grade IV patients;

6. Within 30 days prior to the screening visit, admission due to acute coronary syndrome (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery; Or plan to undergo percutaneous coronary intervention or cardiac surgery within 3 months.

7. Confirmed respiratory system diseases (such as chronic obstructive pulmonary disease, pulmonary arterial hypertension, etc.);

8. History of acute or chronic pancreatitis;

9. Uncontrolled hypertension, defined as systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg (average of three supine blood pressure measurements) during screening visits;

10. Patients with orthostatic hypotension and/or systolic blood pressure<90 mmHg at visit 0 or visit 1, or clinically diagnosed as having low blood volume;

11. Diagnosed malignant tumor patients with an expected life expectancy of less than 1 year;

12. Patients with a history of recurrent urinary and reproductive tract infections (judged by clinical doctors);

13. Patients who participate in other clinical trials within 3 months;

14. Alcohol or drug addiction.

15. In addition to the above, the researchers determined that patients who are not suitable to participate in this clinical trial.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Intervention

Drug:
• Combination therapy
Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid. The dose of metformin from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient&#39;s tolerance situation. The minimum dose is 1000mg/day.
• Sequential treatment group
Metformin, the dose from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient&#39;s tolerance situation. The minimum dose is 1000mg/day. After the fourth week of treatment, blood glucose levels were measured. For those whose blood glucose levels did not meet the standard (fasting blood glucose (FPG)&gt;7mmol/L, postprandial blood glucose (PPG)&gt;10mmol/L), 10 mg qd of Henagliflozin Prolinewas sequentially added. If the blood glucose levels did not meet the standard after 4 weeks of treatment (FPG&gt;7mmol/L, PPG&gt;10mmol/L), 100 mg qd of Ruigeliflozin was added

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Peking University First Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of subjects with HbA1c<7% at 12w		From enrollment to the end of treatment at 12 weeks
Secondary	The proportion of subjects with HbA1c<7% at week 24		From enrollment to the end of treatment at 24 weeks
Secondary	The proportion of subjects with HbA1c<6.5% at 12 week		From enrollment to the end of treatment at 12 weeks
Secondary	The proportion of subjects with HbA1c<6.5% at 24 week		From enrollment to the end of treatment at 24 weeks
Secondary	Changes in HbA1c compared to baseline at 12 weeks		From enrollment to the end of treatment at 12 weeks
Secondary	Changes in HbA1c compared to baseline at 24 weeks		From enrollment to the end of treatment at 24 weeks
Secondary	Changes in fingertip blood glucose (seven point blood glucose spectrum) compared to baseline at 4w, 8w, 12w, and 24w		From enrollment to the end of treatment at 4/8/12/24 weeks
Secondary	Changes in 2hPPG compared to baseline at 4w, 8w, 12w, and 24w		From enrollment to the end of treatment at 4/8/12/24 weeks
Secondary	Changes in FBG compared to baseline at 4w, 8w, 12w, and 24w		From enrollment to the end of treatment at 4/8/12/24 weeks
Secondary	Changes in systolic pressure compared to baseline at 4w, 8w, 12w, and 24w		From enrollment to the end of treatment at 4/8/12/24 weeks
Secondary	Changes in diastolic pressure compared to baseline at 4w, 8w, 12w, and 24w		From enrollment to the end of treatment at 4/8/12/24 weeks
Secondary	Changes in body weight compared to baseline at 4w, 8w, 12w, and 24w		From enrollment to the end of treatment at 4/8/12/24 weeks
Secondary	Changes in waist circumference compared to baseline at 4w, 8w, 12w, and 24w		From enrollment to the end of treatment at 4/8/12/24 weeks
Secondary	Changes in eGFR compared to baseline at 4w, 8w, 12w, and 24w		From enrollment to the end of treatment at 4/8/12/24 weeks
Secondary	Changes in C-peptide levels during the 12 and 24 weeks compared to baseline during abdominal and 2-hour postprandial periods		From enrollment to the end of treatment at 12 and 24 weeks
Secondary	Changes in insulin levels during the 12 and 24 weeks compared to baseline during abdominal and 2-hour postprandial periods		From enrollment to the end of treatment at 12 and 24 weeks